Apr 02, 2026
Appointments support Harmony’s next phase of growth and long‑term value creation PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Apr. 2, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of
Mar 31, 2026
PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Mar. 31, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25 th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 9:30 a.m.
Mar 04, 2026
PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Mar. 4, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will attend the following upcoming investor conferences. Leerink Partners Global Healthcare Conference Date: March 9, 2026 Location: Miami, FL
Feb 24, 2026
WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy Recently Completed Settlements with 3 Additional Generic Filers Toward Goal of Securing WAKIX Franchise Pitolisant GR NDA Submission on Track for Q2 2026;
Feb 17, 2026
PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Feb. 17, 2026-- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for WAKIX ® (pitolisant) tablets for the treatment of cataplexy in pediatric
Feb 10, 2026
PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Feb. 10, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the open of the U.S. financial markets.
